Clinical trial

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00390221

Study summary

ClinicalTrials.gov

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention BIIB019 (Daclizumab High Yield Process) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-02-01

PhasePHASE2

Conditions

Relapsing-Remitting Multiple Sclerosisverified · MONDO: relapsing-remitting multiple sclerosis

Interventions

BIIB019 (Daclizumab High Yield Process)BIOLOGICAL

PlaceboDRUG

Sponsors & collaborators

Biogenlead sponsor

AbbViecollaborator

Mapped research locations

LondonUnited Kingdom1 MoscowRussia1 WarsawPoland1 BudapestHungary1 Saint PetersburgRussia1 KrakowPoland1 LodzPoland1 BialystokPoland1 LublinPoland1 GdanskPoland1 BrnoCzechia1 KharkivUkraine1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00390221 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.